In a report released yesterday, Naz Rahman from Maxim Group maintained a Buy rating on Palisade Bio (PALI – Research Report), with a price target of $5.00. The company’s shares closed yesterday at $1.59.
According to TipRanks, Rahman is a 3-star analyst with an average return of 4.9% and a 38.84% success rate. Rahman covers the Healthcare sector, focusing on stocks such as Quoin Pharmaceuticals, scPharmaceuticals, and Clene.
Palisade Bio has an analyst consensus of Moderate Buy, with a price target consensus of $5.00.
See today’s best-performing stocks on TipRanks >>
PALI market cap is currently $9.19M and has a P/E ratio of -0.14.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Seneca Biopharma, Inc. operates as a biopharmaceutical company, which engages in the research, development, and commercialization of central nervous system therapies based on human neuronal stem cells and small molecule compounds. Its pipeline includes NSI-189 small molecule program, NSI-566 stem cell therapy program, and novel & proprietary chemical entity screening platform. The company was founded by I. Richard Garr, Karl Y. Johe, and Merrill Solomon in 1996 and is headquartered in Germantown, MD.
Read More on PALI:
- Palisade Bio Reports First Quarter 2023 Financial Results
- Palisade Bio Announces Enrollment and Dosing of First Patient in LB1148 Dose Optimization Study
- Palisade Bio Receives Canadian Patent Covering Composition of Lead Program in Development, LB1148
- Palisade Bio receives Canadian patent covering composition of LB1148
- Palisade Bio Announces Enrollment of First Patient in Newsoara Phase 3 Clinical Trial Evaluating LB1148
